APO Research
Talk to an analyst

APO RESEARCH · REPORT

Choroidal Neovascularization Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Choroidal Neovascularization Drug Industry Growth and Trends Forecast to 2032

19 December 2025115 pages

Choose your research edition.

Industry ResearchChoroidal Neovascularization Drug Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Choroidal Neovascularization Drug Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Choroidal Neovascularization Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Choroidal Neovascularization Drug Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Choroidal Neovascularization Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Choroidal Neovascularization Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Choroidal Neovascularization Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Choroidal Neovascularization Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Choroidal Neovascularization Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Choroidal Neovascularization Drug include Eli Lilly and Company, Soligenix, Inc., RxBio, Inc., RedHill Biopharma Ltd., RDD Pharma Ltd., ProCertus BioPharm Inc., Pluristem Therapeutics Inc., PharmaIN Corporation and Onconova Therapeutics, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Choroidal Neovascularization Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Choroidal Neovascularization Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Choroidal Neovascularization Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Choroidal Neovascularization Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Choroidal Neovascularization Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Choroidal Neovascularization Drug Market by Company

Eli Lilly and Company

Soligenix, Inc.

RxBio, Inc.

RedHill Biopharma Ltd.

RDD Pharma Ltd.

ProCertus BioPharm Inc.

Pluristem Therapeutics Inc.

PharmaIN Corporation

Onconova Therapeutics, Inc.

Neumedicines Inc.

Meabco A/S

INSYS Therapeutics, Inc.

Humanetics Corporation

GNI Group Ltd.

Diffusion Pharmaceuticals Inc.

Cumberland Pharmaceuticals, Inc.

Cleveland BioLabs, Inc.

Chrysalis BioTherapeutics, Inc.

Cellphire, Inc.

Choroidal Neovascularization Drug Segment by Type

EWA-001

Entolimod

DG-3

BBT-007

BB-3

AVMOC-001

Others

Choroidal Neovascularization Drug Segment by Application

Clinic

Hospital

Others

Choroidal Neovascularization Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Choroidal Neovascularization Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Choroidal Neovascularization Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Choroidal Neovascularization Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Choroidal Neovascularization Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Choroidal Neovascularization Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of EWA-001 Table 2. Major Company of Entolimod Table 3. Major Company of DG-3 Table 4. Major Company of BBT-007 Table 5. Major Company of BB-3 Table 6. Major Company of AVMOC-001 Table 7. Major Company of Others Table 8. Global Choroidal Neovascularization Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 9. Global Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Units) Table 10. Global Choroidal Neovascularization Drug Sales Market Share in Volume by Type (2021-2026) Table 11. Global Choroidal Neovascularization Drug Sales by Type (2021-2026) & (US$ Million) Table 12. Global Choroidal Neovascularization Drug Sales Market Share in Value by Type (2021-2026) Table 13. Global Choroidal Neovascularization Drug Price by Type (2021-2026) & (US$/Unit) Table 14. Global Choroidal Neovascularization Drug Sales by Type (2027-2032) & (K Units) Table 15. Global Choroidal Neovascularization Drug Sales Market Share in Volume by Type (2027-2032) Table 16. Global Choroidal Neovascularization Drug Sales by Type (2027-2032) & (US$ Million) Table 17. Global Choroidal Neovascularization Drug Sales Market Share in Value by Type (2027-2032) Table 18. Global Choroidal Neovascularization Drug Price by Type (2027-2032) & (US$/Unit) Table 19. North America Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Units) Table 20. North America Choroidal Neovascularization Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Europe Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Units) Table 22. Europe Choroidal Neovascularization Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Asia-Pacific Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Units) Table 24. Asia-Pacific Choroidal Neovascularization Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Latin America Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Units) Table 26. Latin America Choroidal Neovascularization Drug Sales by Type (2021-2026) & (US$ Million) Table 27. Middle East and Africa Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Units) Table 28. Middle East and Africa Choroidal Neovascularization Drug Sales by Type (2021-2026) & (US$ Million) Table 29. Choroidal Neovascularization Drug Industry Trends Table 30. Choroidal Neovascularization Drug Industry Drivers Table 31. Choroidal Neovascularization Drug Industry Opportunities and Challenges Table 32. Choroidal Neovascularization Drug Industry Restraints Table 33. Global Choroidal Neovascularization Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 34. Global Choroidal Neovascularization Drug Revenue Market Share by Company (2021-2026) Table 35. Global Choroidal Neovascularization Drug Sales by Company (2021-2026) & (K Units) Table 36. Global Choroidal Neovascularization Drug Sales Share by Company (2021-2026) Table 37. Global Choroidal Neovascularization Drug Market Price by Company (2021-2026) & (US$/Unit) Table 38. Global Choroidal Neovascularization Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 39. Global Choroidal Neovascularization Drug Major Company Production Sites and Headquarters Table 40. Global Choroidal Neovascularization Drug Company, Product Type & Application Table 41. Global Choroidal Neovascularization Drug Company Establishment Date Table 42. Global Company Market Concentration Ratio (CR5 and HHI) Table 43. Global Choroidal Neovascularization Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 44. Global Choroidal Neovascularization Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 45. Global Choroidal Neovascularization Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Choroidal Neovascularization Drug Sales Market Share in Volume by Region (2021-2026) Table 47. Global Choroidal Neovascularization Drug Sales by Region (2021-2026) & (US$ Million) Table 48. Global Choroidal Neovascularization Drug Sales Market Share in Value by Region (2021-2026) Table 49. Global Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 50. Global Choroidal Neovascularization Drug Sales by Region (2027-2032) & (K Units) Table 51. Global Choroidal Neovascularization Drug Sales Market Share in Volume by Region (2027-2032) Table 52. Global Choroidal Neovascularization Drug Sales by Region (2027-2032) & (US$ Million) Table 53. Global Choroidal Neovascularization Drug Sales Market Share in Value by Region (2027-2032) Table 54. Global Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 55. Global Choroidal Neovascularization Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 56. Global Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Units) Table 57. Global Choroidal Neovascularization Drug Sales Market Share in Volume by Application (2021-2026) Table 58. Global Choroidal Neovascularization Drug Sales by Application (2021-2026) & (US$ Million) Table 59. Global Choroidal Neovascularization Drug Sales Market Share in Value by Application (2021-2026) Table 60. Global Choroidal Neovascularization Drug Price by Application (2021-2026) & (US$/Unit) Table 61. Global Choroidal Neovascularization Drug Sales by Application (2027-2032) & (K Units) Table 62. Global Choroidal Neovascularization Drug Sales Market Share in Volume by Application (2027-2032) Table 63. Global Choroidal Neovascularization Drug Sales by Application (2027-2032) & (US$ Million) Table 64. Global Choroidal Neovascularization Drug Sales Market Share in Value by Application (2027-2032) Table 65. Global Choroidal Neovascularization Drug Price by Application (2027-2032) & (US$/Unit) Table 66. North America Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Units) Table 67. North America Choroidal Neovascularization Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Europe Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Units) Table 69. Europe Choroidal Neovascularization Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Asia-Pacific Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Units) Table 71. Asia-Pacific Choroidal Neovascularization Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Latin America Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Units) Table 73. Latin America Choroidal Neovascularization Drug Sales by Application (2021-2026) & (US$ Million) Table 74. Middle East and Africa Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Units) Table 75. Middle East and Africa Choroidal Neovascularization Drug Sales by Application (2021-2026) & (US$ Million) Table 76. Eli Lilly and Company Company Information Table 77. Eli Lilly and Company Business Overview Table 78. Eli Lilly and Company Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Eli Lilly and Company Choroidal Neovascularization Drug Product Portfolio Table 80. Eli Lilly and Company Recent Development Table 81. Soligenix, Inc. Company Information Table 82. Soligenix, Inc. Business Overview Table 83. Soligenix, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Soligenix, Inc. Choroidal Neovascularization Drug Product Portfolio Table 85. Soligenix, Inc. Recent Development Table 86. RxBio, Inc. Company Information Table 87. RxBio, Inc. Business Overview Table 88. RxBio, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. RxBio, Inc. Choroidal Neovascularization Drug Product Portfolio Table 90. RxBio, Inc. Recent Development Table 91. RedHill Biopharma Ltd. Company Information Table 92. RedHill Biopharma Ltd. Business Overview Table 93. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Portfolio Table 95. RedHill Biopharma Ltd. Recent Development Table 96. RDD Pharma Ltd. Company Information Table 97. RDD Pharma Ltd. Business Overview Table 98. RDD Pharma Ltd. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. RDD Pharma Ltd. Choroidal Neovascularization Drug Product Portfolio Table 100. RDD Pharma Ltd. Recent Development Table 101. ProCertus BioPharm Inc. Company Information Table 102. ProCertus BioPharm Inc. Business Overview Table 103. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Portfolio Table 105. ProCertus BioPharm Inc. Recent Development Table 106. Pluristem Therapeutics Inc. Company Information Table 107. Pluristem Therapeutics Inc. Business Overview Table 108. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Portfolio Table 110. Pluristem Therapeutics Inc. Recent Development Table 111. PharmaIN Corporation Company Information Table 112. PharmaIN Corporation Business Overview Table 113. PharmaIN Corporation Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. PharmaIN Corporation Choroidal Neovascularization Drug Product Portfolio Table 115. PharmaIN Corporation Recent Development Table 116. Onconova Therapeutics, Inc. Company Information Table 117. Onconova Therapeutics, Inc. Business Overview Table 118. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio Table 120. Onconova Therapeutics, Inc. Recent Development Table 121. Neumedicines Inc. Company Information Table 122. Neumedicines Inc. Business Overview Table 123. Neumedicines Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Neumedicines Inc. Choroidal Neovascularization Drug Product Portfolio Table 125. Neumedicines Inc. Recent Development Table 126. Meabco A/S Company Information Table 127. Meabco A/S Business Overview Table 128. Meabco A/S Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Meabco A/S Choroidal Neovascularization Drug Product Portfolio Table 130. Meabco A/S Recent Development Table 131. INSYS Therapeutics, Inc. Company Information Table 132. INSYS Therapeutics, Inc. Business Overview Table 133. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio Table 135. INSYS Therapeutics, Inc. Recent Development Table 136. Humanetics Corporation Company Information Table 137. Humanetics Corporation Business Overview Table 138. Humanetics Corporation Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Humanetics Corporation Choroidal Neovascularization Drug Product Portfolio Table 140. Humanetics Corporation Recent Development Table 141. GNI Group Ltd. Company Information Table 142. GNI Group Ltd. Business Overview Table 143. GNI Group Ltd. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. GNI Group Ltd. Choroidal Neovascularization Drug Product Portfolio Table 145. GNI Group Ltd. Recent Development Table 146. Diffusion Pharmaceuticals Inc. Company Information Table 147. Diffusion Pharmaceuticals Inc. Business Overview Table 148. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Portfolio Table 150. Diffusion Pharmaceuticals Inc. Recent Development Table 151. Cumberland Pharmaceuticals, Inc. Company Information Table 152. Cumberland Pharmaceuticals, Inc. Business Overview Table 153. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Portfolio Table 155. Cumberland Pharmaceuticals, Inc. Recent Development Table 156. Cleveland BioLabs, Inc. Company Information Table 157. Cleveland BioLabs, Inc. Business Overview Table 158. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Portfolio Table 160. Cleveland BioLabs, Inc. Recent Development Table 161. Chrysalis BioTherapeutics, Inc. Company Information Table 162. Chrysalis BioTherapeutics, Inc. Business Overview Table 163. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 164. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio Table 165. Chrysalis BioTherapeutics, Inc. Recent Development Table 166. Cellphire, Inc. Company Information Table 167. Cellphire, Inc. Business Overview Table 168. Cellphire, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 169. Cellphire, Inc. Choroidal Neovascularization Drug Product Portfolio Table 170. Cellphire, Inc. Recent Development Table 171. North America Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 172. North America Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 173. North America Choroidal Neovascularization Drug Sales Market Share by Country (2021-2026) Table 174. North America Choroidal Neovascularization Drug Sales Forecast by Country (2027-2032) & (K Units) Table 175. North America Choroidal Neovascularization Drug Sales Market Share Forecast by Country (2027-2032) Table 176. North America Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. North America Choroidal Neovascularization Drug Market Size by Country (2021-2026) & (US$ Million) Table 178. North America Choroidal Neovascularization Drug Market Share by Country (2021-2026) Table 179. North America Choroidal Neovascularization Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. North America Choroidal Neovascularization Drug Market Share Forecast by Country (2027-2032) Table 181. Europe Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 182. Europe Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 183. Europe Choroidal Neovascularization Drug Sales Market Share by Country (2021-2026) Table 184. Europe Choroidal Neovascularization Drug Sales Forecast by Country (2027-2032) & (K Units) Table 185. Europe Choroidal Neovascularization Drug Sales Market Share Forecast by Country (2027-2032) Table 186. Europe Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Europe Choroidal Neovascularization Drug Market Size by Country (2021-2026) & (US$ Million) Table 188. Europe Choroidal Neovascularization Drug Market Share by Country (2021-2026) Table 189. Europe Choroidal Neovascularization Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Europe Choroidal Neovascularization Drug Market Share Forecast by Country (2027-2032) Table 191. Asia-Pacific Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 192. Asia-Pacific Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 193. Asia-Pacific Choroidal Neovascularization Drug Sales Market Share by Country (2021-2026) Table 194. Asia-Pacific Choroidal Neovascularization Drug Sales Forecast by Country (2027-2032) & (K Units) Table 195. Asia-Pacific Choroidal Neovascularization Drug Sales Market Share Forecast by Country (2027-2032) Table 196. Asia-Pacific Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 197. Asia-Pacific Choroidal Neovascularization Drug Market Size by Country (2021-2026) & (US$ Million) Table 198. Asia-Pacific Choroidal Neovascularization Drug Market Share by Country (2021-2026) Table 199. Asia-Pacific Choroidal Neovascularization Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 200. Asia-Pacific Choroidal Neovascularization Drug Market Share Forecast by Country (2027-2032) Table 201. Latin America Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 202. Latin America Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 203. Latin America Choroidal Neovascularization Drug Sales Market Share by Country (2021-2026) Table 204. Latin America Choroidal Neovascularization Drug Sales Forecast by Country (2027-2032) & (K Units) Table 205. Latin America Choroidal Neovascularization Drug Sales Market Share Forecast by Country (2027-2032) Table 206. Latin America Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 207. Latin America Choroidal Neovascularization Drug Market Size by Country (2021-2026) & (US$ Million) Table 208. Latin America Choroidal Neovascularization Drug Market Share by Country (2021-2026) Table 209. Latin America Choroidal Neovascularization Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 210. Latin America Choroidal Neovascularization Drug Market Share Forecast by Country (2027-2032) Table 211. Middle East and Africa Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 212. Middle East and Africa Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 213. Middle East and Africa Choroidal Neovascularization Drug Sales Market Share by Country (2021-2026) Table 214. Middle East and Africa Choroidal Neovascularization Drug Sales Forecast by Country (2027-2032) & (K Units) Table 215. Middle East and Africa Choroidal Neovascularization Drug Sales Market Share Forecast by Country (2027-2032) Table 216. Middle East and Africa Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 217. Middle East and Africa Choroidal Neovascularization Drug Market Size by Country (2021-2026) & (US$ Million) Table 218. Middle East and Africa Choroidal Neovascularization Drug Market Share by Country (2021-2026) Table 219. Middle East and Africa Choroidal Neovascularization Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 220. Middle East and Africa Choroidal Neovascularization Drug Market Share Forecast by Country (2027-2032) Table 221. Key Raw Materials Table 222. Raw Materials Key Suppliers Table 223. Choroidal Neovascularization Drug Distributors List Table 224. Choroidal Neovascularization Drug Customers List Table 225. Research Programs/Design for This Report Table 226. Authors List of This Report Table 227. Secondary Sources Table 228. Primary Sources List of Figures Figure 1. Choroidal Neovascularization Drug Image Figure 2. Global Choroidal Neovascularization Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Choroidal Neovascularization Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Choroidal Neovascularization Drug Sales (2021-2032) & (K Units) Figure 5. EWA-001 Image Figure 6. Global EWA-001 Sales YoY Growth (2021-2032) & (K Units) Figure 7. Entolimod Image Figure 8. Global Entolimod Sales YoY Growth (2021-2032) & (K Units) Figure 9. DG-3 Image Figure 10. Global DG-3 Sales YoY Growth (2021-2032) & (K Units) Figure 11. BBT-007 Image Figure 12. Global BBT-007 Sales YoY Growth (2021-2032) & (K Units) Figure 13. BB-3 Image Figure 14. Global BB-3 Sales YoY Growth (2021-2032) & (K Units) Figure 15. AVMOC-001 Image Figure 16. Global AVMOC-001 Sales YoY Growth (2021-2032) & (K Units) Figure 17. Others Image Figure 18. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 19. Global Choroidal Neovascularization Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 20. Global Choroidal Neovascularization Drug Market Share by Type 2025 VS 2032 Figure 21. North America Choroidal Neovascularization Drug Sales Market Share in Volume by Type in 2025 Figure 22. North America Choroidal Neovascularization Drug Sales Market Share in Value by Type in 2025 Figure 23. Europe Choroidal Neovascularization Drug Sales Market Share in Volume by Type in 2025 Figure 24. Europe Choroidal Neovascularization Drug Sales Market Share in Value by Type in 2025 Figure 25. Asia-Pacific Choroidal Neovascularization Drug Sales Market Share in Volume by Type in 2025 Figure 26. Asia-Pacific Choroidal Neovascularization Drug Sales Market Share in Value by Type in 2025 Figure 27. Latin America Choroidal Neovascularization Drug Sales Market Share in Volume by Type in 2025 Figure 28. Latin America Choroidal Neovascularization Drug Sales Market Share in Value by Type in 2025 Figure 29. Middle East and Africa Choroidal Neovascularization Drug Sales Market Share in Volume by Type in 2025 Figure 30. Middle East and Africa Choroidal Neovascularization Drug Sales Market Share in Value by Type in 2025 Figure 31. Global Top 5 and 10 Choroidal Neovascularization Drug Players Market Share by Revenue in 2025 Figure 32. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Clinic Image Figure 34. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 35. Hospital Image Figure 36. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 37. Others Image Figure 38. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 39. Global Choroidal Neovascularization Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Choroidal Neovascularization Drug Market Share by Application 2025 VS 2032 Figure 41. North America Choroidal Neovascularization Drug Sales Market Share in Volume by Application in 2025 Figure 42. North America Choroidal Neovascularization Drug Sales Market Share in Value by Application in 2025 Figure 43. Europe Choroidal Neovascularization Drug Sales Market Share in Volume by Application in 2025 Figure 44. Europe Choroidal Neovascularization Drug Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific Choroidal Neovascularization Drug Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific Choroidal Neovascularization Drug Sales Market Share in Value by Application in 2025 Figure 47. Latin America Choroidal Neovascularization Drug Sales Market Share in Volume by Application in 2025 Figure 48. Latin America Choroidal Neovascularization Drug Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa Choroidal Neovascularization Drug Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa Choroidal Neovascularization Drug Sales Market Share in Value by Application in 2025 Figure 51. North America Choroidal Neovascularization Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. North America Choroidal Neovascularization Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America Choroidal Neovascularization Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America Choroidal Neovascularization Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Choroidal Neovascularization Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Europe Choroidal Neovascularization Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Choroidal Neovascularization Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe Choroidal Neovascularization Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Choroidal Neovascularization Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Asia-Pacific Choroidal Neovascularization Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Choroidal Neovascularization Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific Choroidal Neovascularization Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Choroidal Neovascularization Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Latin America Choroidal Neovascularization Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Choroidal Neovascularization Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America Choroidal Neovascularization Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Choroidal Neovascularization Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 68. Middle East and Africa Choroidal Neovascularization Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Choroidal Neovascularization Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa Choroidal Neovascularization Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Choroidal Neovascularization Drug Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. Choroidal Neovascularization Drug Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • EWA-001
  • Entolimod
  • DG-3
  • BBT-007
  • BB-3
  • AVMOC-001
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Eli Lilly and Company
  • Soligenix, Inc.
  • RxBio, Inc.
  • RedHill Biopharma Ltd.
  • RDD Pharma Ltd.
  • ProCertus BioPharm Inc.
  • Pluristem Therapeutics Inc.
  • PharmaIN Corporation
  • Onconova Therapeutics, Inc.
  • Neumedicines Inc.
  • Meabco A/S
  • INSYS Therapeutics, Inc.
  • Humanetics Corporation
  • GNI Group Ltd.
  • Diffusion Pharmaceuticals Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Cleveland BioLabs, Inc.
  • Chrysalis BioTherapeutics, Inc.
  • Cellphire, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Choroidal Neovascularization Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Choroidal Neovascularization Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Choroidal Neovascularization Drug Market by Type
  6. 1.3.1 EWA-001
  7. 1.3.2 Entolimod
  8. 1.3.3 DG-3
  9. 1.3.4 BBT-007
  10. 1.3.5 BB-3
  11. 1.3.6 AVMOC-001
  12. 1.3.7 Others
  13. 1.4 Global Choroidal Neovascularization Drug Market Size by Type
  14. 1.4.1 Global Choroidal Neovascularization Drug Market Size Overview by Type (2021-2032)
  15. 1.4.2 Global Choroidal Neovascularization Drug Historic Market Size Review by Type (2021-2026)
  16. 1.4.3 Global Choroidal Neovascularization Drug Forecasted Market Size by Type (2027-2032)
  17. 1.5 Key Regions Market Size by Type
  18. 1.5.1 North America Choroidal Neovascularization Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.2 Europe Choroidal Neovascularization Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.3 Asia-Pacific Choroidal Neovascularization Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.4 South America Choroidal Neovascularization Drug Sales Breakdown by Type (2021-2026)
  22. 1.5.5 Middle East and Africa Choroidal Neovascularization Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Choroidal Neovascularization Drug Industry Trends
  2. 2.2 Choroidal Neovascularization Drug Industry Drivers
  3. 2.3 Choroidal Neovascularization Drug Industry Opportunities and Challenges
  4. 2.4 Choroidal Neovascularization Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Choroidal Neovascularization Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Choroidal Neovascularization Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Choroidal Neovascularization Drug Price (2021-2026)
  4. 3.4 Global Choroidal Neovascularization Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Choroidal Neovascularization Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Choroidal Neovascularization Drug Company, Product Type & Application
  7. 3.7 Global Choroidal Neovascularization Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Choroidal Neovascularization Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Choroidal Neovascularization Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Choroidal Neovascularization Drug Tier 1, Tier 2, and Tier 3
4 Choroidal Neovascularization Drug Regional Status and Outlook
  1. 4.1 Global Choroidal Neovascularization Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Choroidal Neovascularization Drug Historic Market Size by Region
  3. 4.2.1 Global Choroidal Neovascularization Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Choroidal Neovascularization Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Choroidal Neovascularization Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Choroidal Neovascularization Drug Forecasted Market Size by Region
  7. 4.3.1 Global Choroidal Neovascularization Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Choroidal Neovascularization Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Choroidal Neovascularization Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Choroidal Neovascularization Drug by Application
  1. 5.1 Choroidal Neovascularization Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Choroidal Neovascularization Drug Market Size by Application
  6. 5.2.1 Global Choroidal Neovascularization Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Choroidal Neovascularization Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Choroidal Neovascularization Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Choroidal Neovascularization Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Choroidal Neovascularization Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Choroidal Neovascularization Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Choroidal Neovascularization Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Choroidal Neovascularization Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Eli Lilly and Company
  2. 6.1.1 Eli Lilly and Company Company Information
  3. 6.1.2 Eli Lilly and Company Business Overview
  4. 6.1.3 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Eli Lilly and Company Choroidal Neovascularization Drug Product Portfolio
  6. 6.1.5 Eli Lilly and Company Recent Developments
  7. 6.2 Soligenix, Inc.
  8. 6.2.1 Soligenix, Inc. Company Information
  9. 6.2.2 Soligenix, Inc. Business Overview
  10. 6.2.3 Soligenix, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Soligenix, Inc. Choroidal Neovascularization Drug Product Portfolio
  12. 6.2.5 Soligenix, Inc. Recent Developments
  13. 6.3 RxBio, Inc.
  14. 6.3.1 RxBio, Inc. Company Information
  15. 6.3.2 RxBio, Inc. Business Overview
  16. 6.3.3 RxBio, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 RxBio, Inc. Choroidal Neovascularization Drug Product Portfolio
  18. 6.3.5 RxBio, Inc. Recent Developments
  19. 6.4 RedHill Biopharma Ltd.
  20. 6.4.1 RedHill Biopharma Ltd. Company Information
  21. 6.4.2 RedHill Biopharma Ltd. Business Overview
  22. 6.4.3 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Portfolio
  24. 6.4.5 RedHill Biopharma Ltd. Recent Developments
  25. 6.5 RDD Pharma Ltd.
  26. 6.5.1 RDD Pharma Ltd. Company Information
  27. 6.5.2 RDD Pharma Ltd. Business Overview
  28. 6.5.3 RDD Pharma Ltd. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 RDD Pharma Ltd. Choroidal Neovascularization Drug Product Portfolio
  30. 6.5.5 RDD Pharma Ltd. Recent Developments
  31. 6.6 ProCertus BioPharm Inc.
  32. 6.6.1 ProCertus BioPharm Inc. Company Information
  33. 6.6.2 ProCertus BioPharm Inc. Business Overview
  34. 6.6.3 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Portfolio
  36. 6.6.5 ProCertus BioPharm Inc. Recent Developments
  37. 6.7 Pluristem Therapeutics Inc.
  38. 6.7.1 Pluristem Therapeutics Inc. Company Information
  39. 6.7.2 Pluristem Therapeutics Inc. Business Overview
  40. 6.7.3 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Portfolio
  42. 6.7.5 Pluristem Therapeutics Inc. Recent Developments
  43. 6.8 PharmaIN Corporation
  44. 6.8.1 PharmaIN Corporation Company Information
  45. 6.8.2 PharmaIN Corporation Business Overview
  46. 6.8.3 PharmaIN Corporation Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 PharmaIN Corporation Choroidal Neovascularization Drug Product Portfolio
  48. 6.8.5 PharmaIN Corporation Recent Developments
  49. 6.9 Onconova Therapeutics, Inc.
  50. 6.9.1 Onconova Therapeutics, Inc. Company Information
  51. 6.9.2 Onconova Therapeutics, Inc. Business Overview
  52. 6.9.3 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
  54. 6.9.5 Onconova Therapeutics, Inc. Recent Developments
  55. 6.10 Neumedicines Inc.
  56. 6.10.1 Neumedicines Inc. Company Information
  57. 6.10.2 Neumedicines Inc. Business Overview
  58. 6.10.3 Neumedicines Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Neumedicines Inc. Choroidal Neovascularization Drug Product Portfolio
  60. 6.10.5 Neumedicines Inc. Recent Developments
  61. 6.11 Meabco A/S
  62. 6.11.1 Meabco A/S Company Information
  63. 6.11.2 Meabco A/S Business Overview
  64. 6.11.3 Meabco A/S Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Meabco A/S Choroidal Neovascularization Drug Product Portfolio
  66. 6.11.5 Meabco A/S Recent Developments
  67. 6.12 INSYS Therapeutics, Inc.
  68. 6.12.1 INSYS Therapeutics, Inc. Company Information
  69. 6.12.2 INSYS Therapeutics, Inc. Business Overview
  70. 6.12.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
  72. 6.12.5 INSYS Therapeutics, Inc. Recent Developments
  73. 6.13 Humanetics Corporation
  74. 6.13.1 Humanetics Corporation Company Information
  75. 6.13.2 Humanetics Corporation Business Overview
  76. 6.13.3 Humanetics Corporation Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Humanetics Corporation Choroidal Neovascularization Drug Product Portfolio
  78. 6.13.5 Humanetics Corporation Recent Developments
  79. 6.14 GNI Group Ltd.
  80. 6.14.1 GNI Group Ltd. Company Information
  81. 6.14.2 GNI Group Ltd. Business Overview
  82. 6.14.3 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 GNI Group Ltd. Choroidal Neovascularization Drug Product Portfolio
  84. 6.14.5 GNI Group Ltd. Recent Developments
  85. 6.15 Diffusion Pharmaceuticals Inc.
  86. 6.15.1 Diffusion Pharmaceuticals Inc. Company Information
  87. 6.15.2 Diffusion Pharmaceuticals Inc. Business Overview
  88. 6.15.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Portfolio
  90. 6.15.5 Diffusion Pharmaceuticals Inc. Recent Developments
  91. 6.16 Cumberland Pharmaceuticals, Inc.
  92. 6.16.1 Cumberland Pharmaceuticals, Inc. Company Information
  93. 6.16.2 Cumberland Pharmaceuticals, Inc. Business Overview
  94. 6.16.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Portfolio
  96. 6.16.5 Cumberland Pharmaceuticals, Inc. Recent Developments
  97. 6.17 Cleveland BioLabs, Inc.
  98. 6.17.1 Cleveland BioLabs, Inc. Company Information
  99. 6.17.2 Cleveland BioLabs, Inc. Business Overview
  100. 6.17.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Portfolio
  102. 6.17.5 Cleveland BioLabs, Inc. Recent Developments
  103. 6.18 Chrysalis BioTherapeutics, Inc.
  104. 6.18.1 Chrysalis BioTherapeutics, Inc. Company Information
  105. 6.18.2 Chrysalis BioTherapeutics, Inc. Business Overview
  106. 6.18.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
  108. 6.18.5 Chrysalis BioTherapeutics, Inc. Recent Developments
  109. 6.19 Cellphire, Inc.
  110. 6.19.1 Cellphire, Inc. Company Information
  111. 6.19.2 Cellphire, Inc. Business Overview
  112. 6.19.3 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Cellphire, Inc. Choroidal Neovascularization Drug Product Portfolio
  114. 6.19.5 Cellphire, Inc. Recent Developments
7 North America by Country
  1. 7.1 North America Choroidal Neovascularization Drug Sales by Country
  2. 7.1.1 North America Choroidal Neovascularization Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Choroidal Neovascularization Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Choroidal Neovascularization Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Choroidal Neovascularization Drug Market Size by Country
  6. 7.2.1 North America Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Choroidal Neovascularization Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Choroidal Neovascularization Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Choroidal Neovascularization Drug Sales by Country
  2. 8.1.1 Europe Choroidal Neovascularization Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Choroidal Neovascularization Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Choroidal Neovascularization Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Choroidal Neovascularization Drug Market Size by Country
  6. 8.2.1 Europe Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Choroidal Neovascularization Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Choroidal Neovascularization Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Choroidal Neovascularization Drug Sales by Country
  2. 9.1.1 Asia-Pacific Choroidal Neovascularization Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Choroidal Neovascularization Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Choroidal Neovascularization Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Choroidal Neovascularization Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Choroidal Neovascularization Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Choroidal Neovascularization Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Choroidal Neovascularization Drug Sales by Country
  2. 10.1.1 South America Choroidal Neovascularization Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Choroidal Neovascularization Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Choroidal Neovascularization Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Choroidal Neovascularization Drug Market Size by Country
  6. 10.2.1 South America Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Choroidal Neovascularization Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Choroidal Neovascularization Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Choroidal Neovascularization Drug Sales by Country
  2. 11.1.1 Middle East and Africa Choroidal Neovascularization Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Choroidal Neovascularization Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Choroidal Neovascularization Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Choroidal Neovascularization Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Choroidal Neovascularization Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Choroidal Neovascularization Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Choroidal Neovascularization Drug Value Chain Analysis
  2. 12.1.1 Choroidal Neovascularization Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Choroidal Neovascularization Drug Production Mode & Process
  7. 12.2 Choroidal Neovascularization Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Choroidal Neovascularization Drug Distributors
  10. 12.2.3 Choroidal Neovascularization Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst